UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

ARE NON-RANDOMIZED CONTROLLED STUDIES BEING PUBLISHED IN TOP MEDICAL JOURNALS?

Value in health, 2016-05, Vol.19 (3), p.A282-A282

2016

Volltextzugriff (PDF)

Health care utilization and costs by metabolic syndrome risk factors

Metabolic syndrome and related disorders, 2009-08, Vol.7 (4), p.305-314

2009

Volltextzugriff (PDF)

Economic Evaluation of Paclitaxel Albumin, Paclitaxel, and Docetaxel as a Second Line Treatment for Metastatic Breast Cancer

Value in health, 2014-11, Vol.17 (7), p.A640-A640

2014

Volltextzugriff (PDF)

Calculating The Baseline Fracture Incidence In Non-Risk Patients: A Strategy For Cost-Effectiveness Modeling

Value in health, 2014-05, Vol.17 (3), p.A47-A48

2014

Volltextzugriff (PDF)

PMS29 Cost-Effectiveness of Collagenase Clostridium Histolyticum, Limited Fasciectomy, and Percutaneous Needle Fasciotomy in the Treatment of Dupuytren's Contracture

Value in health, 2012-06, Vol.15 (4), p.A38-A39

2012

Volltextzugriff (PDF)

Bayesian Analysis of Malformation Outcome in Selective Serotonin Reuptake Inhibitor (SSRI) Use During Pregnancy: An Indirect Comparison of Citalopram, Fluoxetine, Paroxetine, and Sertraline

Value in health, 2013-11, Vol.16 (7), p.A544-A544

2013

Volltextzugriff (PDF)

Lifetime costs and life-years gained associated with apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation

Value in health, 2013-05, Vol.16 (3), p.A286-A286

2013

Volltextzugriff (PDF)

Cost-effectiveness analyses for refractory overactive bladder: A systematic literature review

Value in health, 2013-05, Vol.16 (3), p.A182-A182, Article A182

2013

Volltextzugriff (PDF)

PHP64 The Incidence of Potential Drug-Drug Interactions Originating From the Same Prescriber

Value in health, 2012-06, Vol.15 (4), p.A24-A24

2012

Volltextzugriff (PDF)

PUK18 Cost-Effectiveness of Pharmacologic Treatment of Overactive Bladder

Value in health, 2012-06, Vol.15 (4), p.A155-A155

2012

Volltextzugriff (PDF)

PIH1 The Clinical Consequences of Exposure to Clinically Important Drug-Drug Interactions

Value in health, 2012-06, Vol.15 (4), p.A191-A191

2012

Volltextzugriff (PDF)

PSS2 A Systematic Evaluation of Oral Antibiotic and Isotretinoin Therapies for Moderate to Severe Acne

Value in health, 2012-06, Vol.15 (4), p.A250-A250

2012

Volltextzugriff (PDF)

PUK8 Nocturia and the Risk of Falls, Fractures, and Sleep Disturbance: a Systematic Review and Meta-Analysis

Value in health, 2012-06, Vol.15 (4), p.A153-A154

2012

Volltextzugriff (PDF)

HTA17 Cost-Effectiveness Analysis of Capivasertib Plus Fulvestrant in Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2-) Negative Advanced Breast Cancer: A US Payer Perspective

Value in health, 2024-06, Vol.27 (6), p.S247-S247

2024

Volltextzugriff (PDF)

EE29 Cost-Effectiveness of Niraparib Plus Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer

Value in health, 2024-06, Vol.27 (6), p.S62-S62

2024

Volltextzugriff (PDF)

EE204 Cost-Effectiveness Analysis of Patient Self-Management for Managing Warfarin in Patients with Non-Valvular Atrial Fibrillation in the US

Value in health, 2024-06, Vol.27 (6), p.S94-S95

2024

Volltextzugriff (PDF)

PHP85 Evaluation of Prescriber Perceptions of a Near-Real Time Fax Alert Program for Potential Drug-Drug Interactions

Value in health, 2012-06, Vol.15 (4), p.A28-A28

2012

Volltextzugriff (PDF)

PHP13 Impact of Medicare Part D on Pharmaceutical and Medical Utilization in Arizona's Dual Eligible Population

Value in health, 2012-06, Vol.15 (4), p.A15-A15

2012

Volltextzugriff (PDF)

Impact Of Medicare Part D Coverage On Health Outcomes In End-Stage Renal Disease

Value in health, 2013-05, Vol.16 (3), p.A10-A10

2013

Volltextzugriff (PDF)

EE85 A Cost-Utility Analysis Comparing a Clinical Decision Support Software to Prescriber Decision Alone for Drug-Drug Interactions from an U.S. Payer Perspective

Value in health, 2023-06, Vol.26 (6), p.S75-S75

2023

Volltextzugriff (PDF)

EE291 Ethical Implications of Quality-Adjusted Life Year Assessments for Patients with Disabilities: A Duchenne Muscular Dystrophy Case Study

Value in health, 2023-06, Vol.26 (6), p.S112-S112

2023

Volltextzugriff (PDF)

PCR123 Patient-Centric Care (PCC) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): A Global Systematic Literature Review (SLR) and Gap Analysis

Value in health, 2023-06, Vol.26 (6), p.S334-S334

2023

Volltextzugriff (PDF)

EE94 Pharmacogenetic HLA-B58:01 Testing to Prevent Allopurinol-Induced SJS/TEN in Vietnamese Population: A Cost-Effectiveness Analysis

Value in health, 2023-06, Vol.26 (6), p.S76-S77

2023

Volltextzugriff (PDF)

EE153 Cost-Effectiveness of First-Line Nivolumab Combination Therapy Vs Chemotherapy Alone for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Value in health, 2023-06, Vol.26 (6), p.S87-S88

2023

Volltextzugriff (PDF)

CO12 Evaluation of Hyponatremia Risk Among Geriatric Patients Exposed to Selective Serotonin Reuptake Inhibitors (SSRIS) and Thiazide Diuretics

Value in health, 2023-06, Vol.26 (6), p.S15-S16

2023

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(69)

Publikationsform

Artikel
(72)
Tagungsberichte
(1)

Sprache

Englisch
(73)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

ARE NON-RANDOMIZED CONTROLLED STUDIES BEING PUBLISHED IN TOP MEDICAL JOURNALS?

Health care utilization and costs by metabolic syndrome risk factors

Economic Evaluation of Paclitaxel Albumin, Paclitaxel, and Docetaxel as a Second Line Treatment for Metastatic Breast Cancer

Calculating The Baseline Fracture Incidence In Non-Risk Patients: A Strategy For Cost-Effectiveness Modeling

PMS29 Cost-Effectiveness of Collagenase Clostridium Histolyticum, Limited Fasciectomy, and Percutaneous Needle Fasciotomy in the Treatment of Dupuytren's Contracture

Bayesian Analysis of Malformation Outcome in Selective Serotonin Reuptake Inhibitor (SSRI) Use During Pregnancy: An Indirect Comparison of Citalopram, Fluoxetine, Paroxetine, and Sertraline

Lifetime costs and life-years gained associated with apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation

Cost-effectiveness analyses for refractory overactive bladder: A systematic literature review

PHP64 The Incidence of Potential Drug-Drug Interactions Originating From the Same Prescriber

PUK18 Cost-Effectiveness of Pharmacologic Treatment of Overactive Bladder

PIH1 The Clinical Consequences of Exposure to Clinically Important Drug-Drug Interactions

PSS2 A Systematic Evaluation of Oral Antibiotic and Isotretinoin Therapies for Moderate to Severe Acne

PUK8 Nocturia and the Risk of Falls, Fractures, and Sleep Disturbance: a Systematic Review and Meta-Analysis

HTA17 Cost-Effectiveness Analysis of Capivasertib Plus Fulvestrant in Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2-) Negative Advanced Breast Cancer: A US Payer Perspective

EE29 Cost-Effectiveness of Niraparib Plus Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer

EE204 Cost-Effectiveness Analysis of Patient Self-Management for Managing Warfarin in Patients with Non-Valvular Atrial Fibrillation in the US

PHP85 Evaluation of Prescriber Perceptions of a Near-Real Time Fax Alert Program for Potential Drug-Drug Interactions

PHP13 Impact of Medicare Part D on Pharmaceutical and Medical Utilization in Arizona's Dual Eligible Population

Impact Of Medicare Part D Coverage On Health Outcomes In End-Stage Renal Disease

EE85 A Cost-Utility Analysis Comparing a Clinical Decision Support Software to Prescriber Decision Alone for Drug-Drug Interactions from an U.S. Payer Perspective

EE291 Ethical Implications of Quality-Adjusted Life Year Assessments for Patients with Disabilities: A Duchenne Muscular Dystrophy Case Study

PCR123 Patient-Centric Care (PCC) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): A Global Systematic Literature Review (SLR) and Gap Analysis

EE94 Pharmacogenetic HLA-B58:01 Testing to Prevent Allopurinol-Induced SJS/TEN in Vietnamese Population: A Cost-Effectiveness Analysis

EE153 Cost-Effectiveness of First-Line Nivolumab Combination Therapy Vs Chemotherapy Alone for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

CO12 Evaluation of Hyponatremia Risk Among Geriatric Patients Exposed to Selective Serotonin Reuptake Inhibitors (SSRIS) and Thiazide Diuretics

Suchergebnisse filtern